Vagus Nerve Stimulation for Neuropathic Pain

This trial explores a new method to assist individuals with spinal cord injuries experiencing ongoing nerve pain. It employs a device called Transcutaneous Auricular Vagus Nerve Stimulation, which sends gentle electrical signals to an ear area connected to the vagus nerve, potentially easing pain. Participants will receive either the actual treatment or a placebo to determine any differences. The trial seeks individuals with spinal cord injuries who experience nerve pain and have not changed their pain or depression medication in the last six weeks. The primary goals are to assess the treatment's safety, adherence, and effectiveness in reducing pain. As an unphased trial, this study offers a unique opportunity to contribute to pioneering research that could lead to new pain management solutions.

You can continue taking your current medications as long as they have been stable for at least 6 weeks. If your medication dose has changed recently, you may not be eligible for the trial.

Research has shown that transcutaneous auricular vagus nerve stimulation (taVNS) is generally safe. Studies have found that most side effects are mild and temporary. The most common issue, minor skin irritation where the device contacts the skin, occurs in about 8.6% of users but usually resolves quickly.

Unlike standard treatments for neuropathic pain, which often include medications like anticonvulsants and antidepressants, transcutaneous auricular vagus nerve stimulation (taVNS) offers a non-invasive approach. This treatment is unique because it targets the vagus nerve through stimulation delivered directly to the ear, specifically the cymba conchae. Researchers are excited about taVNS because it could provide pain relief without the side effects associated with many medications, offering a promising alternative for those who haven't found relief through traditional methods. Additionally, the sham comparator in the trial helps ensure the observed effects are truly due to vagus nerve activation, enhancing the credibility of the findings.

Research has shown that transcutaneous auricular vagus nerve stimulation (taVNS) may help manage pain in individuals with chronic pain conditions. This trial will assign participants to either an active taVNS group or a sham taVNS group. In one study, taVNS significantly reduced nerve pain in patients with head and neck cancers. Another study found that it relieved pain when combined with a common pain medication. Early data also suggest that taVNS can reduce nerve-related symptoms and improve heart rate variability, indicating better vagus nerve health. Additionally, animal studies have demonstrated that taVNS can greatly reduce pain from nerve injuries.³⁶⁷⁸⁹